Clinical efficacy of decitabine combined with HAG or HAG-like regimen in treatment of acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2018.07.004
- VernacularTitle:地西他滨联合预激方案治疗急性髓系白血病效果观察
- Author:
Wensi SU
1
;
Yi LIN
;
Junjie CAO
;
Kongfei LI
;
Peipei YE
;
Ying LU
Author Information
1. 315040,宁波大学医学院附属鄞州医院血液科
- Keywords:
Leukemia,myeloid,acute;
Decitabine;
New diagnosis;
Recurrence;
Refractory
- From:
Journal of Leukemia & Lymphoma
2018;27(7):400-403
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of decitabine combined with HAG or HAG-like regimen for newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) patients.Methods Thirty-one newly diagnosed (18 cases) and relapsed/refractory (13 cases) AML patients receiving decitabine combined with HAG or HAG-like regimen in Yinzhou Hospital Affiliated to Medical School of Ningbo University from January 2014 to December 2017 were analyzed retrospectively.Results The outcome of 18 newly diagnosed AML patients showed that the overall response rate (ORR) was 77.8 ％ (14/18),including 13 patients achieved complete response (CR) / CR with incomplete blood count recovery (CRi),and the 1-year overall survival (OS) rate was 39.2 ％,the l-year disease free survival (DFS) rate was 32.5 ％.The outcome of 13 relapsed/refractory AML patients showed that the ORR was 53.8 ％ (7/13),including 6 patients achieved CR/CRi,and the 1-year OS rate was 22.4 ％,the 1-year DFS rate was 7.7 ％.Eleven patients were transformed from myelodysplastic syndromes (MDS),the ORR was 90.9 ％ (10/11),including 9 patients achieved CR/CRi,and the 1-year OS and DFS rates were 63.8 ％ and 37.5 ％ respectively.The main adverse events of infection and bleeding were caused by myelosuppression,and non-hematological toxicity included gastrointestinal and liver dysfunction.After the anti-infection and supportive treatment,all 31 patients were safely through bone marrow suppression,with no treatment-related deaths.Conclusions Decitabine combined with HAG or HAG-like regimen is an effective and safe treatment strategy for hypoplastic newly diagnosed and relapsed/refractory AML patients.It is produced relatively higher curative effect for AML patients with MDS transformation.
